Patents Assigned to Universite de la Mediterranee (Aix-Marseille II)
-
Publication number: 20190169630Abstract: The present invention concerns methods and approaches for modifying guanosine tetraphosphate (ppGpp) homeostasis in photosynthetic eukaryotes, in particular plants or algae, in order to modulate senescence for the remobilisation of nitrogen and other nutrients from the chloroplast, and modified photosynthetic eukaryotes thus produced.Type: ApplicationFiled: February 7, 2017Publication date: June 6, 2019Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS ), UNIVERSITE DE LA MEDITERRANEE (AIX-MARSEILLE II)Inventors: Benjamin FIELD, Matteo SUGLIANI, Christophe ROBAGLIA, Hela ABDELKEFI
-
Patent number: 10105384Abstract: The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer.Type: GrantFiled: April 16, 2015Date of Patent: October 23, 2018Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE IIInventors: Palma Rocchi, Virginie Baylot, Julie Acunzo, Claudia Andrieu, Maria Katsogiannou
-
Patent number: 9328143Abstract: The invention relates to peptide derivatives (peptides and pseudo-peptides) and use thereof as vectors for molecules of interest. The invention also relates to conjugates containing a peptide derivative of the invention bound to a molecule of interest. The peptides and prodrug conjugates of the invention can be used to vectorize molecules of pharmaceutical or diagnostic interest, such as, for example, therapeutic molecules, imaging or diagnostic agents, or molecular probes, across cell membranes, and notably to promote their transport across the blood-brain barrier (BBB).Type: GrantFiled: May 14, 2014Date of Patent: May 3, 2016Assignees: VECT-HORUS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE LA MEDITERRANEE (AIX MARSEILLE II)Inventors: Michel Khrestchatisky, Marion David, Yves Molino, Patrick Vlieghe
-
Publication number: 20150353643Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.Type: ApplicationFiled: July 6, 2015Publication date: December 10, 2015Applicants: UNIVERSITE DE LA MEDITERRANEE - Aix-Marseille II, INSTITUT PAOLI-CALMETTES, Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Daniel OLIVE, Marc BONNEVILLE, Emmanuel SCOTET, Christelle HARLY, Yves GUILLAUME
-
Patent number: 9175265Abstract: Mouse or human hematopoietic cells are transduced in vitro with one or more vectors encoding c-Myc and Klf4 genes, to overexpress both c-Myc and Klf4. The transduced cells produce self-renewing populations of macrophages, monocytes, monocyte-derived macrophages, B lymphocytes or erythroid cells. The self-renewing cell populations may include a pharmaceutical composition.Type: GrantFiled: July 8, 2010Date of Patent: November 3, 2015Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite de la Mediterranee (Aix-Marseille II)Inventor: Michael Sieweke
-
Patent number: 9107936Abstract: The present invention concerns antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55), for use as a medicament, in particular for use in the treatment of cell adhesion molecules implicated diseases, notably, MCAM or JAMs implicated diseases. According to some embodiments, said antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55) may be used in the treatment of cancer, metastases, and inflammatory diseases. The present invention further provides methods for screening for compounds liable of treating or preventing such diseases.Type: GrantFiled: February 2, 2012Date of Patent: August 18, 2015Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de la Mediterranee Aix-Marseille IIInventors: Michel Aurrand-Lions, Ana Zarubica
-
Publication number: 20140322235Abstract: The present invention relates to anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vy9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The invention also relates to the use of said antibodies in therapy.Type: ApplicationFiled: December 14, 2011Publication date: October 30, 2014Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), INSTITUT PAOLI-CALMETTES, UNIVERSITE DE LA MEDITERRANEE - Aix-Marseille IIInventors: Daniel Olive, Marc Bonneville, Emmanuel Scotet, Christelle Harly, Yves Guillaume
-
Publication number: 20140286996Abstract: The invention relates to Gram-negative bacteria carrying an inactivated gene encoding a glycosyltransferase involved in the synthesis of the core of the LPS of said Gram-negative bacteria, wherein said inactivated gene results in the synthesis of a LPS having a modified core. These strains have an attenuated virulence but induce a humoral immunity sufficient for ensuring vaccination of the host.Type: ApplicationFiled: June 5, 2014Publication date: September 25, 2014Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique - CNRS, Universite de la Mediterranee - Aix-Marseille II, Universidad de NavarraInventors: Jean-Pierre Gorvel, Vilma Arce Gorvel, Maite Iriarte, Ignacio Moriyon, Raquel Conde-Alvarez
-
Publication number: 20140234342Abstract: The present invention relates to compounds (e.g. antibodies) that specifically bind and inhibit NKp46. Such compounds are capable, when administered to a mammal, capable of increasing the frequency of reactive and/or active NK cells. The invention also relates to pharmaceutical composition and methods of using the antibodies and compositions to treat or prevent diseases, e.g. cancer, infection, autoimmune diseases, inflammatory diseases and the like.Type: ApplicationFiled: June 21, 2012Publication date: August 21, 2014Applicants: INNATE PHARMA, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Emilie Narni-Mancinelli, Sophie Ugolini, Eric Vivier
-
Publication number: 20130309252Abstract: The present invention concerns antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55), for use as a medicament, in particular for use in the treatment of cell adhesion molecules implicated diseases, notably, MCAM or JAMs implicated diseases. According to some embodiments, said antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55) may be used in the treatment of cancer, metastases, and inflammatory diseases. The present invention further provides methods for screening for compounds liable of treating or preventing such diseases.Type: ApplicationFiled: February 2, 2012Publication date: November 21, 2013Applicant: UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE IIInventors: Michel Aurrand-Lions, Ana Zarubica
-
Patent number: 8518914Abstract: The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological aging.Type: GrantFiled: July 5, 2007Date of Patent: August 27, 2013Assignees: Universite de la Mediterranee AIX-Marseille II, Association Francaise Contre les Myophathies (AFM), Assistance Publique Hopitaux de Marseille, Universidad de OviedoInventors: Nicolas Levy, Pierre Cau, Carlos Lopez-Otin
-
Publication number: 20130164268Abstract: The present invention thus relates to stem cells or progenitor cells wherein the expression and/or activity of a member of the glypican family is reduced or abolished for use for the treatment of a pathological condition selected from the group consisting of a degenerative disease, a cardiac disorder, a metabolic disease and an injury by stem cell-based therapy.Type: ApplicationFiled: July 29, 2011Publication date: June 27, 2013Applicant: UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE IIInventors: Rosanna Dono, Annalisa Fico, Flavio Maina
-
Publication number: 20130149306Abstract: The present invention is related to the treatment of certain cancers using antagonists of the binding between a Plexin and a Sema3E. The invention may be helpful in treating primary cancer cell development and metastasis development wherein Sema3E is expressed, in particular overexpressed by the tumoral cells or the stroma. Breast cancer, in particular with distant metastases is concerned. Prostate cancer, melanoma and glioblastoma are also concerned. The antagonist may be any molecule that specifically binds to PlexinD1 or Sema3E and blocks the Sema3E/PlexinD1 binding. In an embodiment, the antagonist is a polypeptide or an antibody.Type: ApplicationFiled: May 6, 2011Publication date: June 13, 2013Applicants: NETRIS PHARMA, CENTRE NATIONAL DE LA DECHERCHE SCIENTIFIQUE (C.N.R.S.), UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE IIInventors: Amélie Royet, Fanny Mann, Sophie Chauvet, Jonathan Luchino
-
Publication number: 20120252012Abstract: The present invention concerns a method of detection and preferably of quantification of DNA, preferably comprising prokaryotic DNA, extracted from a stool sample of an individual, especially for the molecular determination of the composition of the intestinal flora in the stool. According to the invention, one controls the quality of the DNA extraction by verifying whether one detects a specific DNA of Methanobrevibacter smithii and one performs the quantification of said specific prokaryotic DNA for Archae Methanobrevibacter smithii, for the bacterial genus Lactobacillus, for the phylum Bacteroidetes and for the phylum Firmicutes, respectively, to provide a diagnosis and/or monitoring of the weight status of an individual. The present invention provides a method for carrying out the extraction of prokaryotic DNA in stools.Type: ApplicationFiled: April 30, 2010Publication date: October 4, 2012Applicants: ASSISTANCE PUBLIQUE - HOPITAUX DE MARSEILLE, UNIVERSITE DE LA MEDITERRANEE (AIX-MARSEILLE II)Inventors: Fabrice Armougom, Michel Drancourt, Mireille Henry-Mary, Didier Raoult
-
Publication number: 20120141365Abstract: A method for producing hydrogen comprising the steps of: i) contacting a compound (C) comprising one or more groups Si—H with an amine based catalyst in a solvent selected from an alcohol or an aqueous solution, thereby forming hydrogen and a by-product (C1); wherein said amine based catalyst is as defined in claim 1; ii) recovering the obtained hydrogen.Type: ApplicationFiled: February 19, 2010Publication date: June 7, 2012Applicants: Centre National de La Recherche Scientifique (C.N.R.S.), Universite De La Mediterranee Aix-Marseille IIInventor: Jean-Michel Brunel
-
Publication number: 20110311439Abstract: A method for producing hydrogen (H2) includes the steps consisting in: a) reacting a compound (C) including one or more groups Si—H with a fluoride ions source, thereby forming hydrogen and a by-product (C1); and b) recovering the obtained hydrogen.Type: ApplicationFiled: December 16, 2009Publication date: December 22, 2011Applicant: UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE IIInventor: Jean-Michel Brunel
-
Publication number: 20110293634Abstract: The invention relates to antibodies binding to the proteins forming adrenomedullin receptors, and to the uses thereof as a drug.Type: ApplicationFiled: July 31, 2009Publication date: December 1, 2011Applicants: ASSISTANCE PUBLIQUE-HOPITAUX DE MARSEILLE, UNIVERSITE DE LA MEDITERRANEE (AIX-MARSEILLE II)Inventors: L'houcine Ouafik, Kamel Mabrouk, Itidal Kaafarany, Pierre-Marie Martin
-
Publication number: 20110262960Abstract: The present invention relates to a novel mycobacteria culture medium, particularly for mycobacteria of the Mycobacterium tuberculosis complex, that significantly reduces the culture isolation time and thus the time for diagnosing the mycobacteria, particularly those for tuberculosis. A culture medium according to the invention contains defibrinated blood, lecithin, and decomplemented fetal calf serum. The present invention also relates to a culture method and to a method for identifying mycobacteria, particularly bacteria of the Mycobacterium tuberculosis complex. The present invention also relates to a novel decontamination method through chlorhexidine treatment of biological samples in an isolation and mycobacteria culture medium, and to a method for determining by phenotype the sensitivity of mycobacteria to antibiotics by means of a solid culture medium according to the invention.Type: ApplicationFiled: October 20, 2009Publication date: October 27, 2011Applicants: ASSISTANCE PUBLIQUE - HOPITAUX DE MARSEILLE, UNIVERSITE DE LA MEDITERRANEE (AIX-MARSEILLE II)Inventors: Michel Drancourt, Didier Raoult
-
Publication number: 20110165092Abstract: The subject matter of the invention is a cosmetic and/or dermatological composition for use in the treatment of skin and/or hair disorders. More particularly, the invention relates to a cosmetic and/or dermatological composition comprising an inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, an inhibitor of farnesyl pyrophosphate synthase, or an inhibitor of one of the physiologically acceptable salts thereof and a cosmetic and/or dermatological product. The present invention finds, for example, a very advantageous use in the treatment of the effects of early ageing, in particular in terms of the skin and the hair system.Type: ApplicationFiled: December 31, 2008Publication date: July 7, 2011Applicant: Universite de la Mediterranee, Aix-Marseille IIInventors: Pierre Cau, Patrice Bourgeois, Vincent Bonniol, Nicolas Levy
-
Publication number: 20110056543Abstract: The invention aims at a hybrid nanocomposite material comprising electrically conducting inorganic elongated nanocrystals grafted on at least part of the surface thereof with an electrically conducting organic compound, and a preparation process thereof. The invention further discloses thin films, solar cells and switchable devices comprising said hybrid nanocomposite.Type: ApplicationFiled: December 28, 2007Publication date: March 10, 2011Applicant: UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE IIInventors: Jorg Ackermann, Frederic Fages, Cyril Martini